Optimization Of Dolutegravir Solid Dispersion To Enhance Its Solubility By 22 Factorial Designs

The aim of the present study is to enhance, optimise the solubility and to formulate Dolutegravir tablets by using Design Expert® 12 software. Dolutegravir is a HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell. Dolutegravir belongs to BCS class II. Solubility of Dolutegravir -0.095mg/ml in water. Phase solubility and saturation solubility studies of the drug were performed in various solvents. Drug solubility was enhanced using various polymers and different methods. The study was carried out to design an optimised formulation of Dolutegravir solid dispersion using a blend of two solubility enhancers. Interaction effect of Kollidon and Polaxmer-237 1:1 ratio enhances the solubility of the drug. The optimised solid dispersion mixture was used to formulate solid dosage forms (tablets). 89% drug release was observed in 1.5hrs from tablets. Electron micrograph for solid dispersion of Dolutegravir was obtained using scanning electron microscope. Drug Excipient Compatibility Studies of Drug and excipients were performed using TLC and FTIR.